|
1
|
Stupp R, Hegi ME, Mason WP, et al: Effects
of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised
phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kim JH, Bae Kim Y, Han JH, et al:
Pathologic diagnosis of recurrent glioblastoma: morphologic,
immunohistochemical and molecular analysis of 20 paired cases. Am J
Surg Pathol. 36:620–628. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Janbazian L, Karamchandani J and Das S:
Mouse models of glioblastoma: lessons learned and questions to be
answered. J Neurooncol. 118:1–8. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Matozaki T, Murata Y, Saito Y, et al:
Protein tyrosinephosphatase SHP-2: a proto-oncogene product that
promotes Ras activation. Cancer Sci. 100:1786–1793. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zheng H, Alter S and Qu CK: SHP-2 tyrosine
phosphatase in human diseases. Int J Clin Exp Med. 2:17–25.
2009.PubMed/NCBI
|
|
6
|
Bentire-Alj M, Paez JG, David FS, et al:
Activating mutations of the noonan syndrome-associated SHP2/PTPN11
gene in human solid tumors and adult acute myelogenous leukemia.
Cancer Res. 64:8816–8820. 2004. View Article : Google Scholar
|
|
7
|
Zhan Y, Counelis GJ and O'Rourke DM: The
protein tyrosine phosphatase SHP-2 is required for EGFRvIII
oncogenic transformation in human glioblastoma cells. Exp Cell Res.
315:2343–2357. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Louis DN, Ohgaki H, Wiestler OD, et al:
The 2007 WHO classification of tumors of the central nervous
system. Acta Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Maddirela DR, Kesanakurti D, Gujrati M, et
al: MMP-2 suppression abrogates irradiation-induced microtubule
formation in endothelial cells by inhibiting αvβ3-mediated
SDF-1/CXCR4 signaling. Int J Oncol. 42:1279–1288. 2013.PubMed/NCBI
|
|
10
|
Stupp R, Mason WP, van den Bent MJ, et al:
Radiotherapy plusconcomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kargiotis O, Geka A, Rao JS, et al: Review
effects of irradiation on tumor cell survival, invasion and
angiogenesis. J Neurooncol. 100:323–338. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Prise KM, Schettino G, Folkard M, et al:
Review new insights on cell death from radiation exposure. Lancet
Oncol. 6:520–528. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Beal K, Abrey LE and Gutin PH:
Antiangiogenic agents in the treatment of recurrent or newly
diagnosed glioblastoma: analysis of single-agent and combined
modality approaches. Radiat Oncol. 6:22011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hands JR, Abel P, Ashton K, et al:
Investigating the rapid diagnosis of gliomas from serum samples
using infrared spectroscopy and cytokine and angiogenesis factors.
Anal Bioanal Chem. 405:7347–7355. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Brem S, Cotran R and Folkman J: Tumor
angiogenesis: a quantitative method for histologic grading. J Natl
Cancer Inst. 48:347–356. 1972.PubMed/NCBI
|
|
16
|
Conroy T, Desseigne F, Ychou M, et al:
FOLFIRINOX versus gemcitabine formetastatic pancreatic cancer. N
Engl J Med. 364:1817–25. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Milanović D, Firat E, Grosu AL, et al:
Increased radiosensitivity and radiothermosensitivity of human
pancreatic MIA PaCa-2 and U251 glioblastoma cell lines treated with
the novel Hsp90 inhibitor NVP-HSP990. Radiat Oncol. 28:422013.
View Article : Google Scholar
|
|
18
|
Hardee ME and Zagzag D: Mechanisms of
glioma-associated neovascularization. Am J Pathol. 181:1126–1141.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Holash J, Maisonpierre PC, Compton D, et
al: Vessel cooption, regression and growth in tumors mediated by
angiopoietins and VEGF. Science. 284:1994–1998. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zagzag D, Amirnovin R, Greco MA, et al:
Vascular apoptosis andinvolution in gliomas precede
neovascularization: a novel concept for glioma growth and
angiogenesis. Lab Invest. 80:837–849. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lamszus K, Ulbricht U, Matschke J, et al:
Levels of soluble vascular endothelial growth factor (VEGF)
receptor 1 in astrocytic tumors and its relation to malignancy,
vascularity and VEGF-A. Clin Cancer Res. 9:1399–1405.
2003.PubMed/NCBI
|
|
22
|
Reiss Y, Machein MR and Plate KH: The role
of angiopoietins during angiogenesis in gliomas. Brain Pathol.
15:311–17. 2005. View Article : Google Scholar
|
|
23
|
Rong Y, Durden DL, Van Meir EG, et al:
'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic
feature that links vascular pathology, hypoxia and angiogenesis. J
Neuropathol Exp Neurol. 65:529–39. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Norden AD, Young GS, Setayesh K, et al:
Bevacizumab for recurrent malignant gliomas: efficacy, toxicity and
patterns of recurrence. Neurology. 70:779–87. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Narayana A, Kelly P, Golfinos J, et al:
Antiangiogenic therapy using bevacizumab in recurrent high-grade
glioma: impact on local control and patient survival. J Neurosurg.
110:173–80. 2009. View Article : Google Scholar
|
|
26
|
Freeman RM Jr, Plutzky J and Neel BG:
Identification of a human srchomology 2-containing
protein-tyrosine-phosphatase: a putative homolog of Drosophila
corkscrew. Proc Natl Acad Sci USA. 89:11239–11243. 1992. View Article : Google Scholar
|
|
27
|
Barr AJ: Protein tyrosine phosphatases as
drug targets: strategies and challenges of inhibitor development.
Future Med Chem. 2:1563–1576. 2010. View Article : Google Scholar
|
|
28
|
Díaz ME, González L, Miquet JG, et al:
Growth hormone modulation of EGF-induced PI3K-Akt pathway in mice
liver. Cell Signal. 24:514–523. 2012. View Article : Google Scholar
|
|
29
|
Liu KW, Feng H, Bachoo R, et al:
SHP-2/PTPN11 mediates glioma genesis driven by PDGFRA and INK4A/ARF
aberrations in mice and humans. J Clin Invest. 121:905–917. 2011.
View Article : Google Scholar : PubMed/NCBI
|
